Cargando…

The Current Status of the Pharmaceutical Potential of Juniperus L. Metabolites

Background: Plants and their derived natural compounds possess various biological and therapeutic properties, which turns them into an increasing topic of interest and research. Juniperus genus is diverse in species, with several traditional medicines reported, and rich in natural compounds with pot...

Descripción completa

Detalles Bibliográficos
Autores principales: Tavares, Wilson R., Seca, Ana M. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165314/
https://www.ncbi.nlm.nih.gov/pubmed/30065158
http://dx.doi.org/10.3390/medicines5030081
_version_ 1783359807655247872
author Tavares, Wilson R.
Seca, Ana M. L.
author_facet Tavares, Wilson R.
Seca, Ana M. L.
author_sort Tavares, Wilson R.
collection PubMed
description Background: Plants and their derived natural compounds possess various biological and therapeutic properties, which turns them into an increasing topic of interest and research. Juniperus genus is diverse in species, with several traditional medicines reported, and rich in natural compounds with potential for development of new drugs. Methods: The research for this review were based in the Scopus and Web of Science databases using terms combining Juniperus, secondary metabolites names, and biological activities. This is not an exhaustive review of Juniperus compounds with biological activities, but rather a critical selection taking into account the following criteria: (i) studies involving the most recent methodologies for quantitative evaluation of biological activities; and (ii) the compounds with the highest number of studies published in the last four years. Results: From Juniperus species, several diterpenes, flavonoids, and one lignan were emphasized taking into account their level of activity against several targets. Antitumor activity is by far the most studied, being followed by antibacterial and antiviral activities. Deoxypodophyllotoxin and one dehydroabietic acid derivative appears to be the most promising lead compounds. Conclusions: This review demonstrates the Juniperus species value as a source of secondary metabolites with relevant pharmaceutical potential.
format Online
Article
Text
id pubmed-6165314
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61653142018-10-10 The Current Status of the Pharmaceutical Potential of Juniperus L. Metabolites Tavares, Wilson R. Seca, Ana M. L. Medicines (Basel) Review Background: Plants and their derived natural compounds possess various biological and therapeutic properties, which turns them into an increasing topic of interest and research. Juniperus genus is diverse in species, with several traditional medicines reported, and rich in natural compounds with potential for development of new drugs. Methods: The research for this review were based in the Scopus and Web of Science databases using terms combining Juniperus, secondary metabolites names, and biological activities. This is not an exhaustive review of Juniperus compounds with biological activities, but rather a critical selection taking into account the following criteria: (i) studies involving the most recent methodologies for quantitative evaluation of biological activities; and (ii) the compounds with the highest number of studies published in the last four years. Results: From Juniperus species, several diterpenes, flavonoids, and one lignan were emphasized taking into account their level of activity against several targets. Antitumor activity is by far the most studied, being followed by antibacterial and antiviral activities. Deoxypodophyllotoxin and one dehydroabietic acid derivative appears to be the most promising lead compounds. Conclusions: This review demonstrates the Juniperus species value as a source of secondary metabolites with relevant pharmaceutical potential. MDPI 2018-07-31 /pmc/articles/PMC6165314/ /pubmed/30065158 http://dx.doi.org/10.3390/medicines5030081 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Tavares, Wilson R.
Seca, Ana M. L.
The Current Status of the Pharmaceutical Potential of Juniperus L. Metabolites
title The Current Status of the Pharmaceutical Potential of Juniperus L. Metabolites
title_full The Current Status of the Pharmaceutical Potential of Juniperus L. Metabolites
title_fullStr The Current Status of the Pharmaceutical Potential of Juniperus L. Metabolites
title_full_unstemmed The Current Status of the Pharmaceutical Potential of Juniperus L. Metabolites
title_short The Current Status of the Pharmaceutical Potential of Juniperus L. Metabolites
title_sort current status of the pharmaceutical potential of juniperus l. metabolites
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165314/
https://www.ncbi.nlm.nih.gov/pubmed/30065158
http://dx.doi.org/10.3390/medicines5030081
work_keys_str_mv AT tavareswilsonr thecurrentstatusofthepharmaceuticalpotentialofjuniperuslmetabolites
AT secaanaml thecurrentstatusofthepharmaceuticalpotentialofjuniperuslmetabolites
AT tavareswilsonr currentstatusofthepharmaceuticalpotentialofjuniperuslmetabolites
AT secaanaml currentstatusofthepharmaceuticalpotentialofjuniperuslmetabolites